Compare · MDWD vs RLX
MDWD vs RLX
Side-by-side comparison of MediWound Ltd. (MDWD) and RLX Technology Inc. (RLX): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both MDWD and RLX operate in Medicinal Chemicals and Botanical Products (Health Care), so they compete in similar markets.
- RLX is the larger of the two at $3.10B, about 17.0x MDWD ($182.2M).
- Over the past year, MDWD is down 34.1% and RLX is down 9.5% - RLX leads by 24.6 points.
- MDWD has been more active in the news (5 items in the past 4 weeks vs 2 for RLX).
- MDWD has more recent analyst coverage (8 ratings vs 2 for RLX).
- Company
- MediWound Ltd.
- RLX Technology Inc.
- Price
- $14.41+1.55%
- $2.00+0.25%
- Market cap
- $182.2M
- $3.10B
- 1M return
- -17.28%
- -6.98%
- 1Y return
- -34.14%
- -9.50%
- Industry
- Medicinal Chemicals and Botanical Products
- Medicinal Chemicals and Botanical Products
- Exchange
- NASDAQ
- NYSE
- IPO
- 2014
- 2021
- News (4w)
- 5
- 2
- Recent ratings
- 8
- 2
MediWound Ltd.
MediWound Ltd., a biopharmaceutical company, develops, manufactures, and commercializes novel and bio-therapeutic solutions for tissue repair and regeneration. It markets NexoBrid, a biopharmaceutical product for the removal of eschar, a dead or damaged tissue in adults with deep partial- and full-thickness thermal burns to burn centers and hospitals burn units. The company also develops EscharEx, which has completed Phase II clinical trials for the debridement of chronic and other hard-to-heal wounds; MWPC005, a topically applied biological drug candidate that is in Phase I/II clinical trial for the treatment of non-melanoma skin cancers; and MWPC003 for connective tissue disorders. MediWound Ltd. was founded in 2000 and is headquartered in Yavne, Israel.
RLX Technology Inc.
RLX Technology Inc., together with its subsidiaries, researchers, develops, manufactures, distributes, and sells e-vapor products in the People's Republic of China. It serves RELX branded partner stores and other retail outlets through distributors. RLX Technology Inc. was founded in 2018 and is based in Beijing, China.
Latest MDWD
- Director Shamir Nachum bought $83,996 worth of Ordinary Shares (6,000 units at $14.00), increasing direct ownership by 12% to 55,815 units (SEC Form 4)
- Director Fox David Morton bought $49,901 worth of Ordinary Shares (3,537 units at $14.11), increasing direct ownership by 19% to 22,283 units (SEC Form 4)
- Director Rubinstein Samuel bought $2,150 worth of Ordinary Shares (150 units at $14.33), increasing direct ownership by 5% to 2,993 units (SEC Form 4)
- SEC Form 6-K filed by MediWound Ltd.
- MediWound Reports First Quarter 2026 Financial Results and Provides Corporate Update
- SEC Form SCHEDULE 13G filed by MediWound Ltd.
- MediWound to Report First Quarter 2026 Financial Results
- SEC Form 6-K filed by MediWound Ltd.
- Newly Published U.S. Expert Consensus Aligns with MediWound's Strategy for Chronic Wound Debridement
- MediWound to Present New EscharEx® Data at Leading Wound Care Conferences
Latest RLX
- SEC Form 6-K filed by RLX Technology Inc.
- RLX Technology Announces Unaudited First Quarter 2026 Financial Results
- RLX Technology to Report First Quarter 2026 Financial Results on May 20, 2026
- RLX Technology Files 2025 Annual Report on Form 20-F
- SEC Form 20-F filed by RLX Technology Inc.
- SEC Form 3 filed by new insider Wang Ying Kate
- SEC Form 3 filed by new insider Jiang Long
- SEC Form 3 filed by new insider Xi Youmin
- SEC Form 3 filed by new insider Wen Yilong
- SEC Form 3 filed by new insider Lu Chao